Relative Strength Index measures the speed and magnitude of recent price changes on a 0-to-100 scale, showing whether recent trading has leaned stronger or weaker within its range.
Relative Strength Index Analysis Today
Relative Strength Index measures the speed and magnitude of recent price changes on a 0-to-100 scale, showing whether recent trading has leaned stronger or weaker within its range. The current Relative Strength Index for Oramed Pharmaceuticals is 58.87. This reading indicates consistent price behavior relative to the prior session.
On April 25 2026 Oramed Pharmaceuticals was traded for 3.85 at the closing time. The top price for the day was 3.88 and the lowest listed price was 3.77 . Trading activity remained within a narrow range during the period. Price movement on April 25, 2026 remained within defined bounds. The trading delta at closing time against the current closing price is -0.26% .
Readings near the middle of the range usually indicate balanced price behavior, while higher or lower readings reflect stronger directional pressure.
Related Price-Series Methods for Oramed Pharmaceuticals
These methods summarize the same price history through smoothing, range, and momentum calculations. Reviewing them alongside Relative Strength Index helps compare stable sessions with periods of wider price movement in Oramed Pharmaceuticals.
Checking Oramed Pharmaceuticals against related firms within the Health Care space reveals where the stock stands among peers. Market cap and total value checks frame Oramed Pharmaceuticals' size within the competitive field. Peer review is most informative when paired with absolute pricing and trend checks. This type of review is most informative when done often to track how positions shift over time.
Rate of Change and Momentum readings for Oramed Pharmaceuticals measure the velocity of recent price moves rather than direction alone. These indicators add context to how recent sessions in Oramed Pharmaceuticals have behaved.
Standard deviation and variance for Oramed Pharmaceuticals measure total price dispersion, while semi-deviation isolates only the downside moves. Higher variance relative to sector peers signals that Oramed Pharmaceuticals' price path has been less predictable over the measured period.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Oramed Pharmaceuticals Short Properties
Short-interest signals around Oramed Pharmaceuticals reveal whether skeptical positioning is starting to pressure price predictability and market tone. A disciplined short-interest review can make timing decisions more informed under rising skepticism.